Hui Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Tian has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Rongyang Li
Department of Thoracic Surgery Qilu Hospital of Shandong University Jinan Shandong China
34 shared publications - Renchang Zhao
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
33 shared publications - Jin Jiang
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
31 shared publications - Jinghui Liang
The Wistar Institute, Philadelphia, Pennsylvania
31 shared publications - Jingyi Han
Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
31 shared publications - Tao Fang
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
31 shared publications
Latest Publications
- Open Access
Formononetin Alleviates Cigarette Smoke Extract-Induced Lung Injury in Mice with Gut Microbiota and Taurine/SLC6A6/NF-κB Modulation
Cigarette smoke exposure is a major preventable risk factor for respiratory disease and drives oxidative and inflammatory lung injury, highlighting the urgent need for safe, multi-target interventions beyond conventional anti-inflammatory therapy. Formononetin (FMN), a naturally occurring isoflavone with antioxidant, anti-inflammatory, and microbiota-modulating potential, may offer a dietary-botanical strategy against smoke-related pulmonary damage. This study evaluated FMN against cigarette smoke extract (CSE)-induced lung injury and explored its associations with intestinal barrier integrity, gut microbiota, taurine metabolism, SLC6A6 expression, and NF-κB activation. In a CSE-challenged mouse model, oral FMN, particularly at 70 mg/kg, improved body weight gain, reduced the lung index, attenuated pulmonary histopathological injury, restored GSH/GSSG and SOD, decreased MDA, and suppressed TNF-α, IL-1β, and IL-6 expression. FMN also ameliorated colonic injury and restored ZO-1 and occludin expression. Exploratory 16S rRNA sequencing and fecal metabolomics indicated FMN-associated alterations in gut microbial composition and metabolic profiles, with taurine and hypotaurine metabolism identified as a candidate pathway for further investigation. FMN further restored lung taurine content and SLC6A6 expression while inhibiting NF-κB activation. These findings suggest that FMN alleviates CSE-induced lung injury and that this improvement is associated with coordinated changes in gut microbiota composition, taurine metabolism, SLC6A6 expression, and NF-κB activation.
Open AccessFormononetin Alleviates Cigarette Smoke Extract-Induced Lung Injury in Mice with Gut Microbiota and Taurine/SLC6A6/NF-κB Modulation
Cigarette smoke exposure is a major preventable risk factor for respiratory disease and drives oxidative and inflammatory lung injury, highlighting the urgent need for safe, multi-target interventions beyond conventional anti-inflammatory therapy. Formononetin (FMN), a naturally occurring isoflavone with antioxidant, anti-inflammatory, and microbiota-modulating potential, may offer a dietary-botanical strategy against smoke-related pulmonary damage. This study evaluated FMN against cigarette smoke extract (CSE)-induced lung injury and explored its associations with intestinal barrier integrity, gut microbiota, taurine metabolism, SLC6A6 expression, and NF-κB activation. In a CSE-challenged mouse model, oral FMN, particularly at 70 mg/kg, improved body weight gain, reduced the lung index, attenuated pulmonary histopathological injury, restored GSH/GSSG and SOD, decreased MDA, and suppressed TNF-α, IL-1β, and IL-6 expression. FMN also ameliorated colonic injury and restored ZO-1 and occludin expression. Exploratory 16S rRNA sequencing and fecal metabolomics indicated FMN-associated alterations in gut microbial composition and metabolic profiles, with taurine and hypotaurine metabolism identified as a candidate pathway for further investigation. FMN further restored lung taurine content and SLC6A6 expression while inhibiting NF-κB activation. These findings suggest that FMN alleviates CSE-induced lung injury and that this improvement is associated with coordinated changes in gut microbiota composition, taurine metabolism, SLC6A6 expression, and NF-κB activation.
- Open Access
- 28 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Co-stimulatory signal deficiency impairs cytotoxic T lymphocyte function in tumor immune evasion: molecular mechanisms and therapeutic implications
The generation and maintenance of effective tumor-specific CTL responses require more than antigen recognition. In most settings, TCR engagement must be accompanied by co-stimulatory input, with the B7-1/B7-2–CD28 axis being one of the best-characterized examples. When this second signal is weak or absent, tumor-reactive CD8+ T cells may recognize tumor antigens but fail to expand, survive, or acquire and sustain cytotoxic activity. Tumors take advantage of this vulnerability by reducing co-stimulatory ligand availability, increasing inhibitory checkpoint signaling, and remodeling the tumor microenvironment in ways that further restrict T-cell activation. Depending on the stage and context of dysfunction, this shift may favor anergy-like dysfunction, impaired persistence and apoptotic attrition, or, under persistent antigen exposure and sustained inhibitory signaling, exhaustion-associated dysfunction, thereby promoting immune escape. This review examines how reduced or functionally restricted B7–CD28 co-stimulation impairs CTL activation, intratumoral reactivation, and persistence, and how checkpoint signaling, suppressive immune cells, metabolic stress, and stromal barriers compound this defect within tumors. We also evaluate strategies intended to restore or bypass inadequate co-stimulatory input, distinguishing established checkpoint-based interventions from co-stimulatory agonists, engineered T-cell therapies, multispecific antibodies, and gene-based approaches that remain preclinical or early translational in many settings. We propose that mechanism-matched therapy should be guided by the phase at which the dominant barrier arises—tumor-reactive CD8+ T-cell priming, intratumoral CTL reactivation, or long-term CTL persistence.
- 28 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessCo-stimulatory signal deficiency impairs cytotoxic T lymphocyte function in tumor immune evasion: molecular mechanisms and therapeutic implications
The generation and maintenance of effective tumor-specific CTL responses require more than antigen recognition. In most settings, TCR engagement must be accompanied by co-stimulatory input, with the B7-1/B7-2–CD28 axis being one of the best-characterized examples. When this second signal is weak or absent, tumor-reactive CD8+ T cells may recognize tumor antigens but fail to expand, survive, or acquire and sustain cytotoxic activity. Tumors take advantage of this vulnerability by reducing co-stimulatory ligand availability, increasing inhibitory checkpoint signaling, and remodeling the tumor microenvironment in ways that further restrict T-cell activation. Depending on the stage and context of dysfunction, this shift may favor anergy-like dysfunction, impaired persistence and apoptotic attrition, or, under persistent antigen exposure and sustained inhibitory signaling, exhaustion-associated dysfunction, thereby promoting immune escape. This review examines how reduced or functionally restricted B7–CD28 co-stimulation impairs CTL activation, intratumoral reactivation, and persistence, and how checkpoint signaling, suppressive immune cells, metabolic stress, and stromal barriers compound this defect within tumors. We also evaluate strategies intended to restore or bypass inadequate co-stimulatory input, distinguishing established checkpoint-based interventions from co-stimulatory agonists, engineered T-cell therapies, multispecific antibodies, and gene-based approaches that remain preclinical or early translational in many settings. We propose that mechanism-matched therapy should be guided by the phase at which the dominant barrier arises—tumor-reactive CD8+ T-cell priming, intratumoral CTL reactivation, or long-term CTL persistence.
- Open Access
- 12 July 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (13) , e70351
Histone Variant H2A . Z2 Hyper‐Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK – STAT Signaling Pathway
Background: Lung adenocarcinoma (LUAD) is among the most common cancers and a leading cause of cancer‐related deaths. The histone variant H2A.Z has two isoforms (H2A.Z1 and H2A.Z2) encoded by distinct paralogs. Increasing numbers of evidence have demonstrated that H2A.Z1 and H2A.Z2 play a critical role in the pathogenesis of various cancers. Nevertheless, the precise biological functions and underlying mechanisms of H2A.Z in LUAD remain unclear. Methods: The levels of H2A.Z expression in LUAD were evaluated using immunohistochemistry (IHC) and western blot assays. To investigate the biological role of H2A.Z2 in LUAD cells, both in vitro and in vivo experiments were conducted. To evaluate gene expression alterations and predict downstream pathways, transcriptome sequencing was performed. To validate that E2F transcription factor 1 (E2F1) regulates H2A.Z2 expression, dual luciferase reporter assays and chromatin immunoprecipitation (ChIP) assays were used. Results: Herein, we demonstrated high expression pattern of H2A.Z in LUAD tissues and its correlation with adverse clinical outcomes. Functionally, we indicated that H2A.Z2 exerts an oncogenic function in driving LUAD cell proliferation and metastasis. Mechanistically, analysis based on transcriptome sequencing suggested the influence of H2A.Z2 on the JAK–STAT pathway. Rescue experiments revealed that H2A.Z2 promotes LUAD progression by modulating STAT5B. Furthermore, we identified E2F1 as an activator that binds to the H2A.Z2 promoter to drive its transcription, thereby providing a novel mechanism of H2A.Z2 dysregulation. Conclusions: In conclusion, our findings revealed a novel E2F1/H2A.Z2/STAT5B axis accelerating LUAD malignance, suggesting its potential as a promising target for diagnostic and therapeutic interventions in LUAD.
- 12 July 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (13) , e70351
Open AccessHistone Variant H2A . Z2 Hyper‐Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK – STAT Signaling Pathway
Background: Lung adenocarcinoma (LUAD) is among the most common cancers and a leading cause of cancer‐related deaths. The histone variant H2A.Z has two isoforms (H2A.Z1 and H2A.Z2) encoded by distinct paralogs. Increasing numbers of evidence have demonstrated that H2A.Z1 and H2A.Z2 play a critical role in the pathogenesis of various cancers. Nevertheless, the precise biological functions and underlying mechanisms of H2A.Z in LUAD remain unclear. Methods: The levels of H2A.Z expression in LUAD were evaluated using immunohistochemistry (IHC) and western blot assays. To investigate the biological role of H2A.Z2 in LUAD cells, both in vitro and in vivo experiments were conducted. To evaluate gene expression alterations and predict downstream pathways, transcriptome sequencing was performed. To validate that E2F transcription factor 1 (E2F1) regulates H2A.Z2 expression, dual luciferase reporter assays and chromatin immunoprecipitation (ChIP) assays were used. Results: Herein, we demonstrated high expression pattern of H2A.Z in LUAD tissues and its correlation with adverse clinical outcomes. Functionally, we indicated that H2A.Z2 exerts an oncogenic function in driving LUAD cell proliferation and metastasis. Mechanistically, analysis based on transcriptome sequencing suggested the influence of H2A.Z2 on the JAK–STAT pathway. Rescue experiments revealed that H2A.Z2 promotes LUAD progression by modulating STAT5B. Furthermore, we identified E2F1 as an activator that binds to the H2A.Z2 promoter to drive its transcription, thereby providing a novel mechanism of H2A.Z2 dysregulation. Conclusions: In conclusion, our findings revealed a novel E2F1/H2A.Z2/STAT5B axis accelerating LUAD malignance, suggesting its potential as a promising target for diagnostic and therapeutic interventions in LUAD.
- Open Access
- 30 May 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Pan-cancer multi-omics analysis identifies SYNGR4 as a novel clinical prognostic biomarker and therapeutic target in lung adenocarcinoma
Background: While the synaptic vesicle protein SYNGR4 has established roles in the pathobiology of motor neuron disease, its comprehensive oncogenic significance across diverse cancers, and its specific value as a clinical biomarker and therapeutic target in lung adenocarcinoma (LUAD), are entirely unexplored. Methods: Our pan-cancer multi-omics analysis systematically assessed the expression, prognostic value, prognostic nomogram models, and clinical correlates of SYNGR4, investigated its DNA methylation, genetic alterations, and functional pathways (GO/KEGG/GSEA), and evaluated its associations with immune infiltration, immunotherapy response, and drug sensitivity across various cancer types. In addition, we performed qPCR, CCK-8, colony formation, EdU staining, and wound-healing analyses to elucidate the role of SYNGR4 in LUAD proliferation and migration. Results: Our pan-cancer multi-omics results indicate that SYNGR4 is upregulated in multiple cancers and correlates with prognosis. Its expression was linked to DNA methylation, immune cell infiltration and improved responses to PD-1 blockade (nivolumab) and anti-PD-L1 therapy. SYNGR4 expression also showed positive correlations with sensitivity to MEK inhibitors (PD-0325901, Trametinib) and Docetaxel. Pathway analysis linked SYNGR4 to cell cycle progression and synthesis of DNA. In addition, knockdown of SYNGR4 via siRNA suppressed the proliferative and migratory capacities of LUAD cells in vitro. Conclusion: This study establishes SYNGR4 as a novel prognostic biomarker in LUAD, thereby positioning it as a potential therapeutic target with clinical utility.
- 30 May 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessPan-cancer multi-omics analysis identifies SYNGR4 as a novel clinical prognostic biomarker and therapeutic target in lung adenocarcinoma
Background: While the synaptic vesicle protein SYNGR4 has established roles in the pathobiology of motor neuron disease, its comprehensive oncogenic significance across diverse cancers, and its specific value as a clinical biomarker and therapeutic target in lung adenocarcinoma (LUAD), are entirely unexplored. Methods: Our pan-cancer multi-omics analysis systematically assessed the expression, prognostic value, prognostic nomogram models, and clinical correlates of SYNGR4, investigated its DNA methylation, genetic alterations, and functional pathways (GO/KEGG/GSEA), and evaluated its associations with immune infiltration, immunotherapy response, and drug sensitivity across various cancer types. In addition, we performed qPCR, CCK-8, colony formation, EdU staining, and wound-healing analyses to elucidate the role of SYNGR4 in LUAD proliferation and migration. Results: Our pan-cancer multi-omics results indicate that SYNGR4 is upregulated in multiple cancers and correlates with prognosis. Its expression was linked to DNA methylation, immune cell infiltration and improved responses to PD-1 blockade (nivolumab) and anti-PD-L1 therapy. SYNGR4 expression also showed positive correlations with sensitivity to MEK inhibitors (PD-0325901, Trametinib) and Docetaxel. Pathway analysis linked SYNGR4 to cell cycle progression and synthesis of DNA. In addition, knockdown of SYNGR4 via siRNA suppressed the proliferative and migratory capacities of LUAD cells in vitro. Conclusion: This study establishes SYNGR4 as a novel prognostic biomarker in LUAD, thereby positioning it as a potential therapeutic target with clinical utility.
- Open Access
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1834893
Research advances of tubeless thoracic surgery for pulmonary nodules: current status and future challenges
Objective: This narrative review aims to summarize the current research progress on Tubeless thoracic surgery for pulmonary nodules, analyze its physiological basis and clinical applications, and outline future directions. Methods: A literature search was performed in PubMed and Web of Science from database inception to December 2025 using the following Boolean search string: (“Tubeless” OR “non-intubated” OR “spontaneous ventilation”) AND (“VATS” OR “video-assisted thoracoscopic surgery”) AND (“pulmonary nodules” OR “lung nodules” OR “GGN”). A total of 1,902 records were identified. After title and abstract screening independently by two authors, 59 articles were finally included. Eligible studies included randomized controlled trials, prospective and retrospective cohort studies, case series ( n ≥ 10), and expert consensus statements. Only English-language articles were included, as the review is intended for an international readership. Given the heterogeneous nature of the available evidence, this review is presented as a narrative synthesis with no formal quality assessment or meta-analysis. Key findings: Data from heterogeneous studies suggest reductions in laryngeal edema, postoperative nausea and vomiting, pain, and hospital stay, although direct comparisons should be interpreted with caution. However, risks include intraoperative hypercapnia and the potential need for conversion to intubation. Long-term oncological safety remains unconfirmed. Conclusion: In carefully selected patients and experienced centers, available evidence suggests that Tubeless technology may optimize perioperative management and enhance recovery after pulmonary nodule resection. Future efforts should focus on integrating electromagnetic navigation bronchoscopy, artificial intelligence for risk prediction, and day-surgery pathways to maximize clinical and economic benefits.
- 25 May 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 13, 1834893
Open AccessResearch advances of tubeless thoracic surgery for pulmonary nodules: current status and future challenges
Objective: This narrative review aims to summarize the current research progress on Tubeless thoracic surgery for pulmonary nodules, analyze its physiological basis and clinical applications, and outline future directions. Methods: A literature search was performed in PubMed and Web of Science from database inception to December 2025 using the following Boolean search string: (“Tubeless” OR “non-intubated” OR “spontaneous ventilation”) AND (“VATS” OR “video-assisted thoracoscopic surgery”) AND (“pulmonary nodules” OR “lung nodules” OR “GGN”). A total of 1,902 records were identified. After title and abstract screening independently by two authors, 59 articles were finally included. Eligible studies included randomized controlled trials, prospective and retrospective cohort studies, case series ( n ≥ 10), and expert consensus statements. Only English-language articles were included, as the review is intended for an international readership. Given the heterogeneous nature of the available evidence, this review is presented as a narrative synthesis with no formal quality assessment or meta-analysis. Key findings: Data from heterogeneous studies suggest reductions in laryngeal edema, postoperative nausea and vomiting, pain, and hospital stay, although direct comparisons should be interpreted with caution. However, risks include intraoperative hypercapnia and the potential need for conversion to intubation. Long-term oncological safety remains unconfirmed. Conclusion: In carefully selected patients and experienced centers, available evidence suggests that Tubeless technology may optimize perioperative management and enhance recovery after pulmonary nodule resection. Future efforts should focus on integrating electromagnetic navigation bronchoscopy, artificial intelligence for risk prediction, and day-surgery pathways to maximize clinical and economic benefits.
- Open Access
- 6 April 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
NUF2 interacts with BUB3 and drives lung adenocarcinoma progression through activation of the NF-κB pathway
Lung adenocarcinoma (LUAD) is the most common form of lung cancer and is often diagnosed at advanced stages. NUF2, a key component of the NDC80 kinetochore
- 6 April 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Open AccessNUF2 interacts with BUB3 and drives lung adenocarcinoma progression through activation of the NF-κB pathway
Lung adenocarcinoma (LUAD) is the most common form of lung cancer and is often diagnosed at advanced stages. NUF2, a key component of the NDC80 kinetochore
- Open Access
- 8 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (22) , e19836
ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion
Immune checkpoint blockade (ICB) efficacy is limited by tumor‐intrinsic immune escape mechanisms. This study identifies the transcription factor ZBTB21 as a central orchestrator of dual immunosuppressive programs. ZBTB21 epigenetically silences gasdermin D (GSDMD)‐dependent pyroptosis by restricting STAT1‐mediated chromatin accessibility via H3K27ac modulation at the GSDMD locus. Simultaneously, it represses MHC‐I antigen presentation by attenuating IRF1 expression and its transactivation capacity. Genetic ablation of ZBTB21 unleashes pyroptotic cell death and enhances tumor antigen presentation, establishing a self‐reinforcing cycle that recruits and activates CD8 + T cells. This dual activation overcomes ICB resistance in murine models, while B2M deletion ablates efficacy, confirming MHC‐I dependency. Pharmacological inhibition of ZBTB21 with dobutamine disrupts its DNA‐binding domain, which triggers pyroptotic inflammation and MHC‐I upregulation to synergize with anti‐PD‐1 therapy. Thus, ZBTB21 represents a druggable nexus coordinating pyroptosis resistance and antigen presentation escape, providing a combinatorial strategy to reinvigorate antitumor immunity.
- 8 February 2026
- Published by Wiley in Advanced Science
- Vol. 13 (22) , e19836
Open AccessZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion
Immune checkpoint blockade (ICB) efficacy is limited by tumor‐intrinsic immune escape mechanisms. This study identifies the transcription factor ZBTB21 as a central orchestrator of dual immunosuppressive programs. ZBTB21 epigenetically silences gasdermin D (GSDMD)‐dependent pyroptosis by restricting STAT1‐mediated chromatin accessibility via H3K27ac modulation at the GSDMD locus. Simultaneously, it represses MHC‐I antigen presentation by attenuating IRF1 expression and its transactivation capacity. Genetic ablation of ZBTB21 unleashes pyroptotic cell death and enhances tumor antigen presentation, establishing a self‐reinforcing cycle that recruits and activates CD8 + T cells. This dual activation overcomes ICB resistance in murine models, while B2M deletion ablates efficacy, confirming MHC‐I dependency. Pharmacological inhibition of ZBTB21 with dobutamine disrupts its DNA‐binding domain, which triggers pyroptotic inflammation and MHC‐I upregulation to synergize with anti‐PD‐1 therapy. Thus, ZBTB21 represents a druggable nexus coordinating pyroptosis resistance and antigen presentation escape, providing a combinatorial strategy to reinvigorate antitumor immunity.
- Open Access
- 9 January 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1) , 8
RECQL4 promotes the malignant progression of lung adenocarcinoma through the YBX1/G3BP1-mediated NF-κB signaling pathway
Lung adenocarcinoma (LUAD) remains a major global health issue characterized by high incidence and mortality rates. RecQ-like helicase 4 (RECQL4), a member of the DNA helicase family, plays a crucial role in DNA replication, DNA damage repair, and tumor progression. However, its involvement and specific molecular mechanisms in LUAD progression have not been elucidated. Through this investigation, we found that RECQL4 expression was aberrantly elevated in clinical LUAD tissues, and higher levels of RECQL4 expression were associated with poor prognosis and worse clinicopathological characteristics in LUAD patients. Gain-of-function and loss-of-function studies demonstrated that RECQL4 promoted the proliferation, migration, and invasion abilities of LUAD cells. Subsequent gene set enrichment analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis confirmed that RECQL4 activates the NF-κB signaling pathway. Mechanistic investigation indicated that RECQL4 might function as a scaffold protein for the Y box binding protein 1 (YBX1) and GTPase-activating protein SH3 domain-binding protein 1 (G3BP1), enhancing the interaction between YBX1 and G3BP1, thereby activating the NF-κB signaling pathway and promoting the progression of LUAD. In conclusion, RECQL4 promotes the malignant progression of LUAD through the YBX1/G3BP1-mediated NF-κB signaling pathway. These findings suggest that RECQL4 has the potential to serve as a novel prognostic biomarker and an effective therapeutic target for LUAD.
- 9 January 2026
- Published by Springer Nature in Cell Death Discovery
- Vol. 12 (1) , 8
Open AccessRECQL4 promotes the malignant progression of lung adenocarcinoma through the YBX1/G3BP1-mediated NF-κB signaling pathway
Lung adenocarcinoma (LUAD) remains a major global health issue characterized by high incidence and mortality rates. RecQ-like helicase 4 (RECQL4), a member of the DNA helicase family, plays a crucial role in DNA replication, DNA damage repair, and tumor progression. However, its involvement and specific molecular mechanisms in LUAD progression have not been elucidated. Through this investigation, we found that RECQL4 expression was aberrantly elevated in clinical LUAD tissues, and higher levels of RECQL4 expression were associated with poor prognosis and worse clinicopathological characteristics in LUAD patients. Gain-of-function and loss-of-function studies demonstrated that RECQL4 promoted the proliferation, migration, and invasion abilities of LUAD cells. Subsequent gene set enrichment analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis confirmed that RECQL4 activates the NF-κB signaling pathway. Mechanistic investigation indicated that RECQL4 might function as a scaffold protein for the Y box binding protein 1 (YBX1) and GTPase-activating protein SH3 domain-binding protein 1 (G3BP1), enhancing the interaction between YBX1 and G3BP1, thereby activating the NF-κB signaling pathway and promoting the progression of LUAD. In conclusion, RECQL4 promotes the malignant progression of LUAD through the YBX1/G3BP1-mediated NF-κB signaling pathway. These findings suggest that RECQL4 has the potential to serve as a novel prognostic biomarker and an effective therapeutic target for LUAD.
- Open Access
- 28 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
The predictive value of intratumoral tertiary lymphoid structures on the response to immunotherapy in cancer patients: a systematic review and meta-analysis
An increasing number of studies have demonstrated tertiary lymphoid structures (TLS) was associated with prognosis and therapeutic response of immunotherap
- 28 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Open AccessThe predictive value of intratumoral tertiary lymphoid structures on the response to immunotherapy in cancer patients: a systematic review and meta-analysis
An increasing number of studies have demonstrated tertiary lymphoid structures (TLS) was associated with prognosis and therapeutic response of immunotherap